<div id="readability-page-1"><p>Omeros Corporation ((OMER)) has held its Q1 earnings call. Read on for the main highlights of the call.</p><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with  Smart Investor Picks  </li></ul> <p>Omeros Corporation’s latest earnings call struck an upbeat tone as management highlighted the rapid U.S. launch of YARTEMLEA, a strengthened balance sheet, and broad pipeline progress. While executives acknowledged operating losses, debt and earnings volatility tied to convertible notes, the narrative focused on long‑term value creation and cash generation potential from its newly approved therapy.</p> <h2>First-in-Class Approval Anchors Growth Story</h2> <p>YARTEMLEA, a MASP‑2 inhibitor, secured FDA approval as the first and only treatment for TA‑TMA and the first approved inhibitor of the lectin complement pathway. The drug launched in January with initial shipments mid‑month and began generating sales almost immediately, positioning Omeros as first mover in a high‑need rare disease market.</p> <h2>Early Sales Uptake Signals Solid Market Traction</h2> <p>In the first quarter of 2026, YARTEMLEA produced $11.1 million in gross revenue and $9.9 million in net revenue, reflecting an ~11% gross‑to‑net adjustment. By March 31, 30 unique accounts had ordered the drug, including 6 of the top 10 and 24 of the top 80 transplant centers, with distributors able to deliver product within roughly 24 hours.</p> <h2>Rapid Path to Product-Level Cash Generation</h2> <p>Management reported that YARTEMLEA turned cash‑flow positive in its first quarter on the market despite launching mid‑January. Executives also told investors they expect the product’s ramp to be sufficient to push the entire company into positive cash flow within the next 18 months, underscoring its central role in Omeros’ strategy.</p> <h2>Novo Nordisk Deal Delivers Major Non-Dilutive Funding</h2> <p>Omeros emphasized the strategic importance of its zaltenibart transaction with Novo Nordisk, which brought in $240 million in upfront cash at closing and potential near‑term milestones of another $100 million. The deal could be worth up to $2.1 billion in milestones plus high single‑digit to high‑teen royalties, providing substantial non‑dilutive capital to fund operations and the YARTEMLEA rollout.</p> <h2>Strengthened Balance Sheet and Opportunistic Buybacks</h2> <p>At the end of Q1, the company held $135.3 million in cash and investments after retiring its remaining 2026 notes, improving financial flexibility. Omeros also repurchased and retired roughly 360,000 shares at an average price of $11.70 for about $4.2 million, signaling management’s confidence in the long‑term equity value.</p> <h2>Reimbursement Milestones Set to Boost Access</h2> <p>On the reimbursement front, CMS has assigned YARTEMLEA a permanent J‑code effective July 1, which should streamline billing and support adoption. CMS has also proposed YARTEMLEA for New Technology Add‑On Payment status, with a final decision expected in August and potential NTAP effectiveness on October 1, which could strengthen inpatient economics and patient access.</p> <h2>Global Expansion and Label Growth in Focus</h2> <p>Outside the U.S., a marketing authorization application for YARTEMLEA is under EMA review with a decision expected around mid‑year, opening the door to European commercialization. Management is exploring ex‑U.S. partnerships and label expansion into indications such as ARDS, sickle cell disease, acute kidney injury, solid organ transplant‑related TMA and delayed graft function.</p> <h2>Advancing Pipeline Underpins Long-Term Optionality</h2> <p>Omeros highlighted multiple pipeline assets, including a Phase II‑ready long‑acting MASP‑2 antibody, OMS1029, and an oral MASP‑2 small‑molecule program moving toward IND‑enabling studies. OMS527, a PDE7 program funded by NIDA, aims for an inpatient human study by year‑end, while the T‑CAT platform and OncotoX‑AML program showed encouraging scientific and preclinical results heading toward a first‑in‑human trial targeted for late 2027.</p> <h2>Losses Persist Amid Commercial Build-Out</h2> <p>Excluding noncash derivative mark‑to‑market effects, Omeros posted an adjusted net loss of $17.1 million for Q1 2026, or $0.24 per share, reflecting ongoing investment needs. Management cautioned that operating expenses, particularly sales and marketing tied to YARTEMLEA, should tick up slightly in Q2 as the commercial infrastructure scales.</p> <h2>Earnings Volatility from Derivative Accounting</h2> <p>Despite underlying losses, reported Q1 net income was $56.1 million, or $0.78 per share, driven by a $73.1 million noncash gain from remeasuring embedded derivatives on 2029 convertible notes. Management stressed that these mark‑to‑market adjustments are largely driven by stock price and market inputs and can swing quarterly earnings sharply without affecting cash.</p> <h2>Stock Decline and Debt Keep Risk on the Table</h2> <p>The company’s stock dropped from $17.18 at year‑end 2025 to $10.56 at March 31, a 38.5% slide that fueled the derivative gain but highlighted investor caution. Following repayments, Omeros still carries $70.8 million in principal on its unsecured 2029 convertible notes, with Q1 interest expense at $5.9 million and expectations for roughly $7.1 million in interest expense in Q2.</p> <h2>Early Launch Dynamics and Margin Pressures</h2> <p>Management shared limited detail on patient‑level utilization, declining to disclose vials dispensed or patient counts, and noting only 30 ordering accounts by quarter‑end, underscoring the early stage of adoption. Gross‑to‑net deductions were about 11% in Q1 but are expected to stay in the teens and possibly rise as 340B participation grows, which could pressure net revenue per unit.</p> <h2>Guidance Points to Cash-Flow Breakthrough and Key Catalysts</h2> <p>Looking ahead, Omeros is not offering revenue guidance but expects slightly higher Q2 operating expenses, interest expense of around $7.1 million and discontinued‑operations income of about $5 million to $6 million. Management is guiding investors to focus on catalysts such as the July J‑code, potential NTAP approval in August, a mid‑year EMA decision, an OMS527 inpatient study by year‑end and the expectation that YARTEMLEA will drive company‑wide positive cash flow within 18 months.</p> <p>Omeros’ earnings call portrayed a company at an inflection point, balancing near‑term losses and debt against first‑in‑class approval momentum and a fortified cash position. For investors, the key watchpoints will be the pace of YARTEMLEA adoption, reimbursement wins and execution on the pipeline, all of which could validate management’s confidence in a durable growth trajectory.</p></div>

OMER

NVOX

<p>Omeros Corporation's Q1 earnings call highlighted the successful U.S. launch of YARTEMLEA, generating $11.1 million in gross revenue. The company reported a strengthened balance sheet with $135.3 million in cash and a significant deal with Novo Nordisk worth up to $2.1 billion. Despite an adjusted net loss of $17.1 million, management expects YARTEMLEA to drive positive cash flow within 18 months. The stock has declined 38.5% since year-end 2025, raising concerns amid ongoing debt obligations.</p>

Omeros Earnings Call: YARTEMLEA Launch Drives New Phase